In a decision to following information of the deal, executives pointed to near-term release alternatives and pipelines, however some analysts expressed fear in regards to the lack of patent coverage for Revlimid and Opdivo.



Supply hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here